RenataDHA:RENATA +0.09%85 Pretax Margin % is 8.78% as of Mar. 2026, which is 59% below its 10-year median of 21.66. GuruFocus rates DHA:RENATA with a GF Score™ of 85/100 and a GF Value™ of BDT809.93 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 954 Drug Manufacturers companies, Renata ranks worse than 50.73% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Renata's Pre-Tax Income for the
three
months ended in Mar. 2026 was BDT999 Mil. Renata's Revenue for the
three
months ended in Mar. 2026 was BDT11,381 Mil. Therefore, Renata's pretax margin for the quarter that ended in Mar. 2026 was 8.78%.
The historical rank and industry rank for Renata's Pretax Margin % or its related term are showing as below:
DHA:RENATA'
s Pretax Margin % Range Over the Past 10 Years
Min: 5.78 Med: 21.66 Max: 23.82
Current: 7.07
DHA:RENATA's Pretax Margin % is ranked worse than 50.73% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs DHA:RENATA: 7.07
Renata (DHA:RENATA) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Renata Pretax Margin % Related Terms
Renata Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Renata's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:RENATA vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Renata's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renata Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Renata's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Renata's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renata (DHA:RENATA) has a Pretax Margin % of 8.78% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Renata and its competitors. This is 59% below median its historical median of 21.66. Over the past decade, Renata's Pretax Margin % has ranged from 5.78 to 23.82. According to the industry distribution chart, Renata ranks #484 out of 954 companies in the Drug Manufacturers industry, placing it in the top 50.7%.
Is Renata's Pretax Margin % too high?
Renata's current Pretax Margin % of 8.78% is 59% below median its 10-year median of 21.66. Over the past 10 years, this metric has ranged from a low of 5.78 to a high of 23.82. The Drug Manufacturers industry median Pretax Margin % is 7.30. Renata's value of 8.78% is 20.4% above this industry median. Based on the distribution chart, Renata ranks #484 out of 954 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Renata has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Renata's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Renata ranks #484 out of 954 companies for Pretax Margin %. This places Renata in the lower half of its industry. The industry median Pretax Margin % is 7.30. Renata's value of 8.78% is 20.4% above this benchmark. Historically, Renata's own Pretax Margin % has ranged from 5.78 to 23.82 over the past decade. While the company's 10-year median is 21.66 vs. the industry median of 7.30, Renata has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renata's current Pretax Margin % of 8.78% is 20.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Renata and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renata's current Pretax Margin % is 8.78%, which is 59% below median its own 10-year median of 21.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renata stock overvalued right now?
Based on GuruFocus' analysis, Renata (DHA:RENATA) is currently considered Significantly Undervalued. The stock's GF Value™ is BDT809.93, compared to a current price of BDT456.40 — trading 43.6% below its estimated fair value. The current Pretax Margin % is 8.78%, which is 59% below median its 10-year median of 21.66 and 20.4% above the Drug Manufacturers industry median of 7.30. Renata's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Renata (DHA:RENATA), the current Pretax Margin % is 8.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renata (DHA:RENATA) Overvalued in 2026?
Based on GuruFocus' analysis, Renata stock appears to be undervalued.
The current stock price of BDT456.40 is trading 43.6% below its estimated GF Value™ of BDT809.93.
GuruFocus considers Renata to be Significantly Undervalued.
Key valuation signals for DHA:RENATA:
Pretax Margin %: 8.78% (59% below median its 10-year median of 21.66)
GF Value™: BDT809.93 vs. price of BDT456.40 (43.6% below fair value)
Industry Position: 20.4% above the Drug Manufacturers median (#484 of 954)
No single metric tells the full story. See the DHA:RENATA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.
85GF Score
Get the complete analysis for DHA:RENATA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:RENATA has been successfully added to your 
